View ValuationEvonik Industries 将来の成長Future 基準チェック /36Evonik Industries利益と収益がそれぞれ年間30.1%と2.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に8.9% 30.8%なると予測されています。主要情報30.1%収益成長率30.83%EPS成長率Chemicals 収益成長20.8%収益成長率2.3%将来の株主資本利益率8.89%アナリストカバレッジGood最終更新日22 May 2026今後の成長に関する最新情報お知らせ • Sep 26Evonik Industries AG Provides Earnings Guidance for the Third Quarter of 2025Evonik Industries AG provided earnings guidance for the third quarter of 2025. The company expects revenue to be around €3.4 billion in the third quarter of 2025, compared to €3.8 billion in third quarter of 2024.お知らせ • Jul 12Evonik Industries AG Revises Financial Guidance for the Full Year 2023Evonik Industries AG revised financial guidance for the full year 2023. The sales outlook is adjusted to a range between EUR 14 billion and EUR 16 billion (previously: EUR 17 billion to EUR 19 billion).お知らせ • Apr 22Evonik Industries AG Provides Earnings Guidance for the Full Year 2022Evonik Industries AG provided earnings guidance for the full year 2022. For the year, the company expects sales of between €15.5 billion and €16.5 billion.すべての更新を表示Recent updatesお知らせ • May 12Vary Tech, Evonik and Supezet Launch Full-Chain Chemical Recycling Package for Waste Plastics to High-Quality Ppo and Circular NaphthaVary Tech, a global leader in solid waste resource utilization, together with Evonik and SupeZET, officially launched a full-industry chain process package for chemically recycling waste plastics into high-quality Plastic Pyrolysis Oil (PPO) and circular naphtha. The core technology is Vary Tech's oxygen-free pyrolysis, developed over 20 years and six iterations. With a single-unit capacity of 150 tons/day and over 8,000 operating hours annually, it ensures high front-end stability. The PPO then enters Evonik's proprietary Rocket module for upgrading and impurity removal, followed by SupeZET's advanced hydrogenation and fractionation for deep refining. The complete chain — feedstock pretreatment, continuous pyrolysis, deep purification, and product offtake — directly outputs circular naphtha and high-quality PPO meeting international petrochemical standards. This ensures seamless entry into global petrochemical and low-carbon fuel supply chains, removing technical barriers to the high-end circular economy. As the core engine, Vary Tech's oxygen-free pyrolysis technology offers broad feedstock compatibility. Beyond waste plastics, it has been applied to waste tires, oil sludge, industrial hazardous waste, medical waste, and new energy solid waste, with over 100 commercial pyrolysis lines delivered globally. While building chemical recycling, Vary Tech also leads in mechanical recycling. Leveraging 16 years of self-operated plant experience and its "high-end equipment manufacturing + industrial operation" dual-drive model, Vary Tech showcased its AI-powered intelligent home appliance dismantling system at the exhibition. Achieving 200 units per hour — a global efficiency record — the system delivers high-purity separation of all e-waste categories. Vary Tech has empowered Haier, TCL, and Midea, providing green recycling services for over 130 million obsolete appliances worldwide. From mechanical to chemical recycling, Vary Tech is integrating global supply chain resources to deliver scalable, economical, and sustainable technical solutions for global climate action and circular economy goals.Reported Earnings • May 11First quarter 2026 earnings released: EPS: €0.27 (vs €0.50 in 1Q 2025)First quarter 2026 results: EPS: €0.27 (down from €0.50 in 1Q 2025). Revenue: €3.43b (down 9.3% from 1Q 2025). Net income: €125.0m (down 46% from 1Q 2025). Profit margin: 3.6% (down from 6.2% in 1Q 2025). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.お知らせ • Apr 17Evonik Industries AG, Annual General Meeting, Jun 03, 2026Evonik Industries AG, Annual General Meeting, Jun 03, 2026, at 10:00 W. Europe Standard Time.Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €16.44, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 13x in the Chemicals industry in Europe. Total returns to shareholders of 2.3% over the past three years.New Risk • Mar 08New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 43% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (176% payout ratio). Large one-off items impacting financial results.Declared Dividend • Mar 02Dividend reduced to €1.00Dividend of €1.00 is 15% lower than last year. Ex-date: 4th June 2026 Payment date: 8th June 2026 Dividend yield will be 7.0%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is covered by both earnings (74% earnings payout ratio) and cash flows (67% cash payout ratio). The dividend has not increased over the past 10 years but has been stable with no material reductions to payments, indicating a long track record of dividend stability. EPS is expected to decline by 19% over the next 3 years. A fall of 18% would increase the payout ratio to a potentially unsustainable range, which means the dividend may be at risk.Declared Dividend • Feb 08Dividend reduced to €1.00Dividend of €1.00 is 15% lower than last year. Ex-date: 4th June 2026 Payment date: 8th June 2026 Dividend yield will be 6.7%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is covered by both earnings (74% earnings payout ratio) and cash flows (67% cash payout ratio). The dividend has not increased over the past 10 years but has been stable with no material reductions to payments, indicating a long track record of dividend stability. EPS is expected to decline by 19% over the next 3 years. A fall of 18% would increase the payout ratio to a potentially unsustainable range, which means the dividend may be at risk.Reported Earnings • Feb 06Full year 2025 earnings released: EPS: €1.36 (vs €0.48 in FY 2024)Full year 2025 results: EPS: €1.36 (up from €0.48 in FY 2024). Revenue: €14.1b (down 7.2% from FY 2024). Net income: €634.0m (up 186% from FY 2024). Profit margin: 4.5% (up from 1.5% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.お知らせ • Feb 06Evonik Industries AG announces Annual dividend, payable on June 08, 2026Evonik Industries AG announced Annual dividend of EUR 1.0000 per share payable on June 08, 2026, ex-date on June 04, 2026 and record date on June 05, 2026.お知らせ • Nov 06+ 2 more updatesEvonik Industries AG to Report Q1, 2026 Results on May 08, 2026Evonik Industries AG announced that they will report Q1, 2026 results on May 08, 2026Reported Earnings • Nov 05Third quarter 2025 earnings released: €0.23 loss per share (vs €0.48 profit in 3Q 2024)Third quarter 2025 results: €0.23 loss per share (down from €0.48 profit in 3Q 2024). Revenue: €3.39b (down 12% from 3Q 2024). Net loss: €106.0m (down 148% from profit in 3Q 2024). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 9% per year.お知らせ • Oct 06Evonik Industries AG to Report Q4, 2025 Results on Mar 04, 2026Evonik Industries AG announced that they will report Q4, 2025 results on Mar 04, 2026お知らせ • Sep 26Evonik Industries AG Provides Earnings Guidance for the Third Quarter of 2025Evonik Industries AG provided earnings guidance for the third quarter of 2025. The company expects revenue to be around €3.4 billion in the third quarter of 2025, compared to €3.8 billion in third quarter of 2024.Reported Earnings • Aug 03Second quarter 2025 earnings released: EPS: €0.26 (vs €0.011 loss in 2Q 2024)Second quarter 2025 results: EPS: €0.26 (up from €0.011 loss in 2Q 2024). Revenue: €3.50b (down 11% from 2Q 2024). Net income: €120.0m (up €125.0m from 2Q 2024). Profit margin: 3.4% (up from net loss in 2Q 2024). Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.Upcoming Dividend • May 22Upcoming dividend of €1.17 per shareEligible shareholders must have bought the stock before 29 May 2025. Payment date: 03 June 2025. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 5.8%. Within top quartile of Austrian dividend payers (4.8%). Higher than average of industry peers (2.5%).Reported Earnings • May 13First quarter 2025 earnings released: EPS: €0.50 (vs €0.33 in 1Q 2024)First quarter 2025 results: EPS: €0.50 (up from €0.33 in 1Q 2024). Revenue: €3.78b (flat on 1Q 2024). Net income: €233.0m (up 49% from 1Q 2024). Profit margin: 6.2% (up from 4.1% in 1Q 2024). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.Declared Dividend • Mar 31Dividend of €1.17 announcedDividend of €1.17 is the same as last year. Ex-date: 29th May 2025 Payment date: 2nd June 2025 Dividend yield will be 5.9%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is not covered by earnings (246% earnings payout ratio). However, it is covered by cash flows (62% cash payout ratio). The dividend has increased by an average of 1.6% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 173% to bring the payout ratio under control. EPS is expected to grow by 114% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio.お知らせ • Mar 06Evonik Industries AG announces Annual dividend, payable on June 02, 2025Evonik Industries AG announced Annual dividend of EUR 1.1700 per share payable on June 02, 2025, ex-date on May 29, 2025 and record date on May 30, 2025.Reported Earnings • Nov 08Third quarter 2024 earnings released: EPS: €0.48 (vs €0.21 loss in 3Q 2023)Third quarter 2024 results: EPS: €0.48 (up from €0.21 loss in 3Q 2023). Revenue: €3.83b (up 1.6% from 3Q 2023). Net income: €223.0m (up €319.0m from 3Q 2023). Profit margin: 5.8% (up from net loss in 3Q 2023). Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.お知らせ • Sep 20Evonik Industries AG to Report Q1, 2025 Results on May 12, 2025Evonik Industries AG announced that they will report Q1, 2025 results on May 12, 2025お知らせ • Sep 04+ 1 more updateEvonik Industries AG to Report Q2, 2025 Results on Aug 01, 2025Evonik Industries AG announced that they will report Q2, 2025 results on Aug 01, 2025Reported Earnings • Aug 02Second quarter 2024 earnings released: €0.01 loss per share (vs €0.58 loss in 2Q 2023)Second quarter 2024 results: €0.01 loss per share (improved from €0.58 loss in 2Q 2023). Revenue: €3.93b (up 1.1% from 2Q 2023). Net loss: €5.00m (loss narrowed 98% from 2Q 2023). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.Upcoming Dividend • May 29Upcoming dividend of €1.17 per shareEligible shareholders must have bought the stock before 05 June 2024. Payment date: 07 June 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 5.8%. Lower than top quartile of Austrian dividend payers (6.1%). Higher than average of industry peers (2.7%).Reported Earnings • May 09First quarter 2024 earnings released: EPS: €0.33 (vs €0.10 in 1Q 2023)First quarter 2024 results: EPS: €0.33 (up from €0.10 in 1Q 2023). Revenue: €3.80b (down 5.2% from 1Q 2023). Net income: €156.0m (up 232% from 1Q 2023). Profit margin: 4.1% (up from 1.2% in 1Q 2023). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.お知らせ • Apr 20+ 1 more updateEvonik Industries AG, Annual General Meeting, May 28, 2025Evonik Industries AG, Annual General Meeting, May 28, 2025.Reported Earnings • Mar 05Full year 2023 earnings released: €1.00 loss per share (vs €1.16 profit in FY 2022)Full year 2023 results: €1.00 loss per share (down from €1.16 profit in FY 2022). Revenue: €15.3b (down 17% from FY 2022). Net loss: €465.0m (down 186% from profit in FY 2022). Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.お知らせ • Mar 05International Chemical Investors S.E. agreed to acquire Superabsorbents business of Evonik.International Chemical Investors S.E. agreed to acquire Superabsorbents business of Evonik on March 4, 2024. The business to be sold generated sales of €892 million in 2023, with adjusted EBITDA in the mid double-digit million euro range. The final transfer of the business is planned for mid-2024 following approval by the relevant competition authorities.お知らせ • Jan 16Lanxess Reportedly Seeks to Sell Polyurethane OpsLANXESS Aktiengesellschaft (XTRA:LXS) has initiated a process to sell its polyurethane business, which could be valued at between EUR 500 million (USD 547.2 million) and EUR 600 million, German paper Handelsblatt reported on January 15, 2024. The company has engaged Deutsche Bank to search for a buyer, Handelsblatt said, citing people familiar with the matter. Chemical companies such as Evonik Industries AG (XTRA:EVK), Stockmeier, or Plixxent, are considered possible interested parties. With the sale, Lanxess aims to completely exit the plastics market as the company has transformed into a producer of ingredients for food, cosmetics, and pharmaceuticals.Reported Earnings • Nov 08Third quarter 2023 earnings released: €0.21 loss per share (vs €0.46 profit in 3Q 2022)Third quarter 2023 results: €0.21 loss per share (down from €0.46 profit in 3Q 2022). Revenue: €3.77b (down 23% from 3Q 2022). Net loss: €96.0m (down 145% from profit in 3Q 2022). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 11Second quarter 2023 earnings released: €0.58 loss per share (vs €0.64 profit in 2Q 2022)Second quarter 2023 results: €0.58 loss per share (down from €0.64 profit in 2Q 2022). Revenue: €3.89b (down 19% from 2Q 2022). Net loss: €270.0m (down 191% from profit in 2Q 2022). Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.お知らせ • Aug 10+ 3 more updatesEvonik Industries AG to Report Q1, 2024 Results on May 08, 2024Evonik Industries AG announced that they will report Q1, 2024 results on May 08, 2024お知らせ • Jul 12Evonik Industries AG Revises Financial Guidance for the Full Year 2023Evonik Industries AG revised financial guidance for the full year 2023. The sales outlook is adjusted to a range between EUR 14 billion and EUR 16 billion (previously: EUR 17 billion to EUR 19 billion).お知らせ • Jun 09RAG Stiftung Not in Hurry to Cut Evonik StakeRAG-Stiftung is not in a hurry to reduce its stake in chemicals firm Evonik Industries AG (XTRA:EVK) as the foundation is not under financial pressure, RAG chairman Bernd Toenjes said at a press conference as quotes by German paper Frankfurter Allgemeine Zeitung (FAZ). RAG Stiftung, which owns 54.9% in the chemicals company, plans to cut its stake to a blocking minority in the future. The shareholding may fall below the majority threshold soon. According to Toenjes, a convertible bond is due in 2024, providing an opportunity to reach 50% by the end of 2024. For the moment, Evonik remains one of the most important assets for RAG Stiftung.Upcoming Dividend • May 25Upcoming dividend of €1.17 per share at 5.9% yieldEligible shareholders must have bought the stock before 01 June 2023. Payment date: 05 June 2023. The company is paying out more than 100% of its profits and is paying out 81% of its cash flow. Trailing yield: 5.9%. Within top quartile of Austrian dividend payers (5.4%). Higher than average of industry peers (4.0%).Reported Earnings • May 10First quarter 2023 earnings released: EPS: €0.10 (vs €0.67 in 1Q 2022)First quarter 2023 results: EPS: €0.10 (down from €0.67 in 1Q 2022). Revenue: €4.01b (down 11% from 1Q 2022). Net income: €47.0m (down 85% from 1Q 2022). Profit margin: 1.2% (down from 7.0% in 1Q 2022). Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 03Full year 2022 earnings released: EPS: €1.16 (vs €1.61 in FY 2021)Full year 2022 results: EPS: €1.16 (down from €1.61 in FY 2021). Revenue: €18.5b (up 24% from FY 2021). Net income: €539.0m (down 28% from FY 2021). Profit margin: 2.9% (down from 5.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.6% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.お知らせ • Dec 30SABO S.p.A. acquired TAA derivatives business from Evonik Industries AG (XTRA:EVK).SABO S.p.A. agreed to acquire TAA derivatives business from Evonik Industries AG (XTRA:EVK) on October 21, 2022. On the sales price, no details are disclosed. The transaction is subject to approval by the competent Evonik committees. Around 250 employees to transfer to new owner. Around 250 people are working at the two production sites in Marl, Germany, and Liaoyang, China. The closing is expected to be in early 2023. SABO S.p.A. completed the acquisition of TAA derivatives business from Evonik Industries AG (XTRA:EVK) on December 29, 2022.Reported Earnings • Nov 10Third quarter 2022 earnings released: EPS: €0.46 (vs €0.49 in 3Q 2021)Third quarter 2022 results: EPS: €0.46 (down from €0.49 in 3Q 2021). Revenue: €4.88b (up 26% from 3Q 2021). Net income: €214.0m (down 7.4% from 3Q 2021). Profit margin: 4.4% (down from 6.0% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • Nov 02Kensing, LLC completed the acquisition of Amphoteric Surfactants and Specialty Esters Manufacturing Operations in Hopewell, Virginia from Evonik Industries AG (XTRA:EVK).Kensing, LLC entered into an agreement to acquire Amphoteric Surfactants and Specialty Esters Manufacturing Operations in Hopewell, Virginia from Evonik Industries AG (XTRA:EVK) on July 28, 2022. The transaction is subject to regulatory approvals and customary closing conditions. The transaction is expected to close in the third quarter of 2022. Kensing, LLC completed the acquisition of Amphoteric Surfactants and Specialty Esters Manufacturing Operations in Hopewell, Virginia from Evonik Industries AG (XTRA:EVK) on November 1, 2022お知らせ • Oct 12+ 2 more updatesEvonik Industries AG to Report Q2, 2023 Results on Aug 04, 2023Evonik Industries AG announced that they will report Q2, 2023 results on Aug 04, 2023Reported Earnings • Aug 11Second quarter 2022 earnings released: EPS: €0.64 (vs €0.48 in 2Q 2021)Second quarter 2022 results: EPS: €0.64 (up from €0.48 in 2Q 2021). Revenue: €4.77b (up 31% from 2Q 2021). Net income: €297.0m (up 34% from 2Q 2021). Profit margin: 6.2% (up from 6.1% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is expected to shrink by 1.9% compared to a 14% growth forecast for the industry in Austria. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • Aug 03Kensing, LLC entered into an agreement to acquire Amphoteric Surfactants and Specialty Esters Manufacturing Operations in Hopewell, Virginia from Evonik Industries AG (XTRA:EVK)Kensing, LLC entered into an agreement to acquire Amphoteric Surfactants and Specialty Esters Manufacturing Operations in Hopewell, Virginia from Evonik Industries AG (XTRA:EVK) on July 28, 2022. The transaction is subject to regulatory approvals and customary closing conditions. The transaction is expected to close in the third quarter of 2022.お知らせ • Jun 25Evonik Industries AG, Annual General Meeting, May 31, 2023Evonik Industries AG, Annual General Meeting, May 31, 2023. Agenda: Annual shareholders' meeting 2023.Upcoming Dividend • May 19Upcoming dividend of €1.17 per shareEligible shareholders must have bought the stock before 26 May 2022. Payment date: 31 May 2022. Payout ratio is a comfortable 63% and this is well supported by cash flows. Trailing yield: 4.5%. Within top quartile of Austrian dividend payers (4.5%). Higher than average of industry peers (3.4%).Reported Earnings • May 06First quarter 2022 earnings released: EPS: €0.67 (vs €0.41 in 1Q 2021)First quarter 2022 results: EPS: €0.67 (up from €0.41 in 1Q 2021). Revenue: €4.50b (up 34% from 1Q 2021). Net income: €314.0m (up 63% from 1Q 2021). Profit margin: 7.0% (up from 5.7% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 1.8%, compared to a 17% growth forecast for the industry in Austria. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • Apr 22Evonik Industries AG Provides Earnings Guidance for the Full Year 2022Evonik Industries AG provided earnings guidance for the full year 2022. For the year, the company expects sales of between €15.5 billion and €16.5 billion.Reported Earnings • Mar 05Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: €1.61 (up from €1.05 in FY 2020). Revenue: €15.0b (up 23% from FY 2020). Net income: €748.0m (up 53% from FY 2020). Profit margin: 5.0% (up from 4.0% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.1%. Over the next year, revenue is forecast to grow 2.9%, compared to a 12% growth forecast for the industry in Austria. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has remained flat.お知らせ • Mar 04Evonik Industries AG to Report Q4, 2022 Results on Mar 02, 2023Evonik Industries AG announced that they will report Q4, 2022 results on Mar 02, 2023Reported Earnings • Nov 06Third quarter 2021 earnings released: EPS €0.49 (vs €0.32 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €3.87b (up 33% from 3Q 2020). Net income: €231.0m (up 55% from 3Q 2020). Profit margin: 6.0% (up from 5.1% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Reported Earnings • Aug 06Second quarter 2021 earnings released: EPS €0.48 (vs €0.26 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €3.64b (up 29% from 2Q 2020). Net income: €221.0m (up 77% from 2Q 2020). Profit margin: 6.1% (up from 4.4% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.お知らせ • Aug 04Evonik Industries AG (XTRA:EVK) acquired JeNaCell GmbH.Evonik Industries AG (XTRA:EVK) acquired JeNaCell GmbH on August 2, 2021. Upon completion the employees of JeNaCell will continue to work at the development and production site based in Jena, Germany and JeNaCell's portfolio will be integrated into Evonik's health care business. Evonik Industries AG (XTRA:EVK) completed the acquisition of JeNaCell GmbH on August 2, 2021.お知らせ • Jun 23Orion Engineered Carbons S.A. Settles Dispute with Evonik Industries AGOrion Engineered Carbons S.A. announced its agreement with Evonik Industries AG to settle the arbitration proceedings which Orion (Germany) had commenced against an Evonik Industries AG affiliate in June 2019. The arbitration was launched by Orion to enforce - among others - indemnity claims covering capital expenditures and costs to remedy past violations of the U.S. Clean Air Act alleged by the U.S. Environmental Protection Agency (U.S. EPA). According to the settlement, Evonik agrees to make a one-time cash payment of €66.55 million (approximately $79.3 million) to Orion which resolves the claims and counterclaims the parties raised in the arbitration. The settled dispute between Orion and Evonik originates from the acquisition of the carbon black business by Rhône Capital and Triton after the business was spun-out of Evonik in 2011. The 2011 acquisition agreement provided for a partial indemnity from Evonik against various exposures, including capital investments, fines and costs arising in connection with U.S. Clean Air Act violations that allegedly occurred prior to the closing of the 2011 acquisition (i.e., under Evonik’s control). The respective claims raised by the U.S. EPA were ultimately resolved by a Consent Decree between Orion and the U.S. EPA in June 2018. Under the Consent Decree, Orion became obligated to install certain capital-intensive pollution control equipment at its U.S. carbon black plants. In June 2019, Orion initiated arbitration proceedings to enforce its environmental indemnity claims against Evonik, and Evonik in turn submitted certain counterclaims related to tax indemnities and cost reimbursements against Orion. The settlement now reached by Orion and Evonik terminates the arbitration and puts an end to a legal controversy that lasted for almost a decade.Upcoming Dividend • May 27Upcoming dividend of €1.15 per shareEligible shareholders must have bought the stock before 03 June 2021. Payment date: 08 June 2021. Trailing yield: 4.0%. Within top quartile of Austrian dividend payers (3.2%). Higher than average of industry peers (2.3%).Reported Earnings • May 07First quarter 2021 earnings released: EPS €0.41 (vs €0.29 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €3.36b (up 3.5% from 1Q 2020). Net income: €193.0m (up 42% from 1Q 2020). Profit margin: 5.7% (up from 4.2% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.お知らせ • Mar 10+ 1 more updateCassava Sciences Announces Pharmaceutical Supply Agreement for SimufilamCassava Sciences, Inc. announced it has entered into a drug supply agreement with Evonik Industries AG for simufilam. Under the agreement, Evonik will supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for the treatment of Alzheimer’s disease.Reported Earnings • Mar 06Full year 2020 earnings releasedThe company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €12.2b (down 6.9% from FY 2019). Net income: €489.0m (down 35% from FY 2019). Profit margin: 4.0% (down from 5.7% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has remained flat, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Mar 06Revenue beats expectationsRevenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 5.8%, compared to a 5.8% growth forecast for the Chemicals industry in Austria.Is New 90 Day High Low • Feb 20New 90-day high: €28.03The company is up 18% from its price of €23.83 on 20 November 2020. The Austrian market is also up 18% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Chemicals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €53.22 per share.お知らせ • Feb 13Evonik Industries AG to Report Q4, 2020 Results on Mar 04, 2021Evonik Industries AG announced that they will report Q4, 2020 results on Mar 04, 2021Is New 90 Day High Low • Jan 29New 90-day high: €27.45The company is up 32% from its price of €20.82 on 30 October 2020. The Austrian market is up 39% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €52.93 per share.Is New 90 Day High Low • Jan 06New 90-day high: €27.33The company is up 16% from its price of €23.50 on 08 October 2020. The Austrian market is up 27% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €53.41 per share.お知らせ • Jan 06Evonik Industries AG (XTRA:EVK) completed the acquisition of LACTEL Absorbable Polymer Product Line of DURECT Corporation (NasdaqCM:DRRX) for $15 million.Evonik Industries AG (XTRA:EVK) signed an agreement to acquire LACTEL Absorbable Polymer Product Line of DURECT Corporation (NasdaqCM:DRRX) for $15 million on December 4, 2020. Under the terms of the agreement, Evonik agreed to pay DURECT the sum of $15 million in exchange for certain assets and liabilities associated with LACTEL product line based in Birmingham, Alabama, plus an additional potential payment based on full year EBITDAS results. The consideration is subject to adjustments based on the year-end net working capital. An offer will be extended to each of the 15 employees of DURECT located in Birmingham, Alabama, which are associated with the LACTEL® business to transition to Evonik. The transaction is subject to certain customary closing conditions and is expected to occur by the first quarter of 2021. Evonik Industries AG (XTRA:EVK) completed the acquisition of LACTEL Absorbable Polymer Product Line of DURECT Corporation (NasdaqCM:DRRX) on January 4, 2021.Is New 90 Day High Low • Dec 16New 90-day high: €26.75The company is up 15% from its price of €23.28 on 17 September 2020. The Austrian market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €44.44 per share.お知らせ • Dec 12Evonik Industries AG to Report Q2, 2021 Results on Aug 05, 2021Evonik Industries AG announced that they will report Q2, 2021 results on Aug 05, 2021Is New 90 Day High Low • Nov 24New 90-day high: €25.11The company is up 2.0% from its price of €24.67 on 26 August 2020. The Austrian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €39.61 per share.お知らせ • Nov 20+ 1 more updateEvonik Industries AG to Report Q3, 2021 Results on Nov 04, 2021Evonik Industries AG announced that they will report Q3, 2021 results on Nov 04, 2021Reported Earnings • Nov 05Third quarter 2020 earnings released: EPS €0.32The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2020 results: Revenue: €2.92b (down 9.7% from 3Q 2019). Net income: €149.0m (down 2.6% from 3Q 2019). Profit margin: 5.1% (up from 4.7% in 3Q 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.Analyst Estimate Surprise Post Earnings • Nov 05Revenue beats expectationsRevenue exceeded analyst estimates by 0.1%. Over the next year, revenue is forecast to grow 3.9% while the growth in Chemicals industry in Austria is expected to stay flat.Is New 90 Day High Low • Oct 21New 90-day low: €21.93The company is down 12% from its price of €24.87 on 23 July 2020. The Austrian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €36.16 per share.Is New 90 Day High Low • Sep 26New 90-day low: €21.99The company is down 4.0% from its price of €22.84 on 26 June 2020. The Austrian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €40.52 per share.お知らせ • Aug 27Evonik Industries AG (XTRA:EVK) entered into a definitive agreement to acquire Porocel Corporation for $210 million.Evonik Industries AG (XTRA:EVK) entered into a definitive agreement to acquire Porocel Corporation for $210 million on August 26, 2020. The purchase price (enterprise value) is 9.1x times adjusted earnings before interest, tax, depreciation and amortization (EBITDA) in 2019. The transaction will be financed out of Evonik's strong cash position. Porocel generated sales of approximately $100 million and EBITDA of about $23 million in 2019. The transaction is expected to close by the end of 2020 and is subject to approval by the relevant authorities. Evonik expects to increase sales of the combined catalyst business to significantly more than $591 million (€500 million) by the end of 2025 without the need for investment in new capacities. RBC Capital Markets acted as financial advisor and Thompson Hine LLP acted as legal advisor to Porocel. Dieter Schmitz (US), Matthew Grant (Canada), Tracy Wut (China), Jean-Francois Findling (Luxembourg), Andrew Martin (Singapore), John Murphy, Garry Jaunal, Kai Kramer, Doug Sanders, Jessica Wicha, Brian Zurawski and Richard Wells of Baker McKenzie acted as legal advisor to Evonik Industries.お知らせ • Jul 31Evonik Industries AG (XTRA:EVK) completed the acquisition of Innovativehealth Group,s.lEvonik Industries AG (XTRA:EVK) entered into an agreement to acquire to acquire Innovativehealth Group,s.l on March 19, 2020. Innovativehealth will be part of Evonik's Care Solutions Business Line. The transaction is expected to close before the end of March 2020. Evonik Industries AG (XTRA:EVK) completed the acquisition of Innovativehealth Group,s.l on April 1, 2020. Innovativehealth GROUP,S.L. will be part of Evonik's Care Solutions Business Line.お知らせ • Jul 30United Initiators GmbH completed the acquisition of Hydrogen Peroxide (H2O2) plant of Evonik Industries AG (XTRA:EVK).United Initiators GmbH agreed to acquire Hydrogen Peroxide (H2O2) plant of Evonik Industries AG (XTRA:EVK) on January 28, 2020. The sale has been initiated to address the Competition Bureau about its proposed transaction for the takeover of PeroxyChem Holding Company LLC. The deal has been approved by the Competition Bureau. United Initiators GmbH completed the acquisition of Hydrogen Peroxide (H2O2) plant of Evonik Industries AG (XTRA:EVK) on January 28, 2020.業績と収益の成長予測WBAG:EVK - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202814,7435798311,6661012/31/202714,4655338391,6101312/31/202614,4734497991,561123/31/202613,7191576831,465N/A12/31/202514,0692656951,443N/A9/30/202514,265944561,269N/A6/30/202514,7074235131,325N/A3/31/202515,1382999411,720N/A12/31/202415,1572228731,713N/A9/30/202415,1632291,2161,978N/A6/30/202415,102-901,3282,072N/A3/31/202415,058-3569071,745N/A12/31/202315,267-4658011,594N/A9/30/202316,002-6048891,789N/A6/30/202317,109-2957081,675N/A3/31/202317,9952726731,568N/A12/31/202218,4885397851,650N/A9/30/202218,2389261741,100N/A6/30/202217,2319444101,284N/A3/31/202216,0958697501,630N/A12/31/202114,9557489291,815N/A9/30/202114,0787241,1962,086N/A6/30/202113,1246429841,920N/A3/31/202112,3145469701,924N/A12/31/202012,1994897711,727N/A9/30/202012,2706145731,482N/A6/30/202012,5856175071,403N/A3/31/202013,0656793701,259N/A12/31/201913,108753N/A1,321N/A9/30/201913,084506N/A1,517N/A6/30/201913,199624N/A1,619N/A3/31/201913,306673N/A1,826N/A12/31/201813,267686N/A1,760N/A9/30/201813,580841N/A1,708N/A6/30/201813,789797N/A1,877N/A3/31/201813,994788N/A1,567N/A12/31/201714,383713N/A1,551N/A9/30/201714,015723N/A1,667N/A6/30/201713,623718N/A1,449N/A3/31/201713,262656N/A1,708N/A12/31/201612,732748N/A1,769N/A9/30/201612,725758N/A1,774N/A6/30/201612,926725N/A1,982N/A3/31/201613,188981N/A1,863N/A12/31/201513,5071,008N/A1,971N/A9/30/201513,5351,027N/A1,776N/A6/30/201513,4131,004N/A1,373N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: EVKの予測収益成長率 (年間30.1% ) は 貯蓄率 ( 2.3% ) を上回っています。収益対市場: EVKの収益 ( 30.1% ) はAustrian市場 ( 11.3% ) よりも速いペースで成長すると予測されています。高成長収益: EVKの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: EVKの収益 ( 2.3% ) Austrian市場 ( 4% ) よりも低い成長が予測されています。高い収益成長: EVKの収益 ( 2.3% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: EVKの 自己資本利益率 は、3年後には低くなると予測されています ( 8.9 %)。成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 16:03終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Evonik Industries AG 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。31 アナリスト機関Anil ShenoyBarclaysAndreas HeineBarclaysSebastian BrayBerenberg28 その他のアナリストを表示
お知らせ • Sep 26Evonik Industries AG Provides Earnings Guidance for the Third Quarter of 2025Evonik Industries AG provided earnings guidance for the third quarter of 2025. The company expects revenue to be around €3.4 billion in the third quarter of 2025, compared to €3.8 billion in third quarter of 2024.
お知らせ • Jul 12Evonik Industries AG Revises Financial Guidance for the Full Year 2023Evonik Industries AG revised financial guidance for the full year 2023. The sales outlook is adjusted to a range between EUR 14 billion and EUR 16 billion (previously: EUR 17 billion to EUR 19 billion).
お知らせ • Apr 22Evonik Industries AG Provides Earnings Guidance for the Full Year 2022Evonik Industries AG provided earnings guidance for the full year 2022. For the year, the company expects sales of between €15.5 billion and €16.5 billion.
お知らせ • May 12Vary Tech, Evonik and Supezet Launch Full-Chain Chemical Recycling Package for Waste Plastics to High-Quality Ppo and Circular NaphthaVary Tech, a global leader in solid waste resource utilization, together with Evonik and SupeZET, officially launched a full-industry chain process package for chemically recycling waste plastics into high-quality Plastic Pyrolysis Oil (PPO) and circular naphtha. The core technology is Vary Tech's oxygen-free pyrolysis, developed over 20 years and six iterations. With a single-unit capacity of 150 tons/day and over 8,000 operating hours annually, it ensures high front-end stability. The PPO then enters Evonik's proprietary Rocket module for upgrading and impurity removal, followed by SupeZET's advanced hydrogenation and fractionation for deep refining. The complete chain — feedstock pretreatment, continuous pyrolysis, deep purification, and product offtake — directly outputs circular naphtha and high-quality PPO meeting international petrochemical standards. This ensures seamless entry into global petrochemical and low-carbon fuel supply chains, removing technical barriers to the high-end circular economy. As the core engine, Vary Tech's oxygen-free pyrolysis technology offers broad feedstock compatibility. Beyond waste plastics, it has been applied to waste tires, oil sludge, industrial hazardous waste, medical waste, and new energy solid waste, with over 100 commercial pyrolysis lines delivered globally. While building chemical recycling, Vary Tech also leads in mechanical recycling. Leveraging 16 years of self-operated plant experience and its "high-end equipment manufacturing + industrial operation" dual-drive model, Vary Tech showcased its AI-powered intelligent home appliance dismantling system at the exhibition. Achieving 200 units per hour — a global efficiency record — the system delivers high-purity separation of all e-waste categories. Vary Tech has empowered Haier, TCL, and Midea, providing green recycling services for over 130 million obsolete appliances worldwide. From mechanical to chemical recycling, Vary Tech is integrating global supply chain resources to deliver scalable, economical, and sustainable technical solutions for global climate action and circular economy goals.
Reported Earnings • May 11First quarter 2026 earnings released: EPS: €0.27 (vs €0.50 in 1Q 2025)First quarter 2026 results: EPS: €0.27 (down from €0.50 in 1Q 2025). Revenue: €3.43b (down 9.3% from 1Q 2025). Net income: €125.0m (down 46% from 1Q 2025). Profit margin: 3.6% (down from 6.2% in 1Q 2025). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
お知らせ • Apr 17Evonik Industries AG, Annual General Meeting, Jun 03, 2026Evonik Industries AG, Annual General Meeting, Jun 03, 2026, at 10:00 W. Europe Standard Time.
Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €16.44, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 13x in the Chemicals industry in Europe. Total returns to shareholders of 2.3% over the past three years.
New Risk • Mar 08New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 43% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (176% payout ratio). Large one-off items impacting financial results.
Declared Dividend • Mar 02Dividend reduced to €1.00Dividend of €1.00 is 15% lower than last year. Ex-date: 4th June 2026 Payment date: 8th June 2026 Dividend yield will be 7.0%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is covered by both earnings (74% earnings payout ratio) and cash flows (67% cash payout ratio). The dividend has not increased over the past 10 years but has been stable with no material reductions to payments, indicating a long track record of dividend stability. EPS is expected to decline by 19% over the next 3 years. A fall of 18% would increase the payout ratio to a potentially unsustainable range, which means the dividend may be at risk.
Declared Dividend • Feb 08Dividend reduced to €1.00Dividend of €1.00 is 15% lower than last year. Ex-date: 4th June 2026 Payment date: 8th June 2026 Dividend yield will be 6.7%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is covered by both earnings (74% earnings payout ratio) and cash flows (67% cash payout ratio). The dividend has not increased over the past 10 years but has been stable with no material reductions to payments, indicating a long track record of dividend stability. EPS is expected to decline by 19% over the next 3 years. A fall of 18% would increase the payout ratio to a potentially unsustainable range, which means the dividend may be at risk.
Reported Earnings • Feb 06Full year 2025 earnings released: EPS: €1.36 (vs €0.48 in FY 2024)Full year 2025 results: EPS: €1.36 (up from €0.48 in FY 2024). Revenue: €14.1b (down 7.2% from FY 2024). Net income: €634.0m (up 186% from FY 2024). Profit margin: 4.5% (up from 1.5% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
お知らせ • Feb 06Evonik Industries AG announces Annual dividend, payable on June 08, 2026Evonik Industries AG announced Annual dividend of EUR 1.0000 per share payable on June 08, 2026, ex-date on June 04, 2026 and record date on June 05, 2026.
お知らせ • Nov 06+ 2 more updatesEvonik Industries AG to Report Q1, 2026 Results on May 08, 2026Evonik Industries AG announced that they will report Q1, 2026 results on May 08, 2026
Reported Earnings • Nov 05Third quarter 2025 earnings released: €0.23 loss per share (vs €0.48 profit in 3Q 2024)Third quarter 2025 results: €0.23 loss per share (down from €0.48 profit in 3Q 2024). Revenue: €3.39b (down 12% from 3Q 2024). Net loss: €106.0m (down 148% from profit in 3Q 2024). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 9% per year.
お知らせ • Oct 06Evonik Industries AG to Report Q4, 2025 Results on Mar 04, 2026Evonik Industries AG announced that they will report Q4, 2025 results on Mar 04, 2026
お知らせ • Sep 26Evonik Industries AG Provides Earnings Guidance for the Third Quarter of 2025Evonik Industries AG provided earnings guidance for the third quarter of 2025. The company expects revenue to be around €3.4 billion in the third quarter of 2025, compared to €3.8 billion in third quarter of 2024.
Reported Earnings • Aug 03Second quarter 2025 earnings released: EPS: €0.26 (vs €0.011 loss in 2Q 2024)Second quarter 2025 results: EPS: €0.26 (up from €0.011 loss in 2Q 2024). Revenue: €3.50b (down 11% from 2Q 2024). Net income: €120.0m (up €125.0m from 2Q 2024). Profit margin: 3.4% (up from net loss in 2Q 2024). Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • May 22Upcoming dividend of €1.17 per shareEligible shareholders must have bought the stock before 29 May 2025. Payment date: 03 June 2025. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 5.8%. Within top quartile of Austrian dividend payers (4.8%). Higher than average of industry peers (2.5%).
Reported Earnings • May 13First quarter 2025 earnings released: EPS: €0.50 (vs €0.33 in 1Q 2024)First quarter 2025 results: EPS: €0.50 (up from €0.33 in 1Q 2024). Revenue: €3.78b (flat on 1Q 2024). Net income: €233.0m (up 49% from 1Q 2024). Profit margin: 6.2% (up from 4.1% in 1Q 2024). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
Declared Dividend • Mar 31Dividend of €1.17 announcedDividend of €1.17 is the same as last year. Ex-date: 29th May 2025 Payment date: 2nd June 2025 Dividend yield will be 5.9%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is not covered by earnings (246% earnings payout ratio). However, it is covered by cash flows (62% cash payout ratio). The dividend has increased by an average of 1.6% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 173% to bring the payout ratio under control. EPS is expected to grow by 114% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio.
お知らせ • Mar 06Evonik Industries AG announces Annual dividend, payable on June 02, 2025Evonik Industries AG announced Annual dividend of EUR 1.1700 per share payable on June 02, 2025, ex-date on May 29, 2025 and record date on May 30, 2025.
Reported Earnings • Nov 08Third quarter 2024 earnings released: EPS: €0.48 (vs €0.21 loss in 3Q 2023)Third quarter 2024 results: EPS: €0.48 (up from €0.21 loss in 3Q 2023). Revenue: €3.83b (up 1.6% from 3Q 2023). Net income: €223.0m (up €319.0m from 3Q 2023). Profit margin: 5.8% (up from net loss in 3Q 2023). Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
お知らせ • Sep 20Evonik Industries AG to Report Q1, 2025 Results on May 12, 2025Evonik Industries AG announced that they will report Q1, 2025 results on May 12, 2025
お知らせ • Sep 04+ 1 more updateEvonik Industries AG to Report Q2, 2025 Results on Aug 01, 2025Evonik Industries AG announced that they will report Q2, 2025 results on Aug 01, 2025
Reported Earnings • Aug 02Second quarter 2024 earnings released: €0.01 loss per share (vs €0.58 loss in 2Q 2023)Second quarter 2024 results: €0.01 loss per share (improved from €0.58 loss in 2Q 2023). Revenue: €3.93b (up 1.1% from 2Q 2023). Net loss: €5.00m (loss narrowed 98% from 2Q 2023). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.
Upcoming Dividend • May 29Upcoming dividend of €1.17 per shareEligible shareholders must have bought the stock before 05 June 2024. Payment date: 07 June 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 5.8%. Lower than top quartile of Austrian dividend payers (6.1%). Higher than average of industry peers (2.7%).
Reported Earnings • May 09First quarter 2024 earnings released: EPS: €0.33 (vs €0.10 in 1Q 2023)First quarter 2024 results: EPS: €0.33 (up from €0.10 in 1Q 2023). Revenue: €3.80b (down 5.2% from 1Q 2023). Net income: €156.0m (up 232% from 1Q 2023). Profit margin: 4.1% (up from 1.2% in 1Q 2023). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 20+ 1 more updateEvonik Industries AG, Annual General Meeting, May 28, 2025Evonik Industries AG, Annual General Meeting, May 28, 2025.
Reported Earnings • Mar 05Full year 2023 earnings released: €1.00 loss per share (vs €1.16 profit in FY 2022)Full year 2023 results: €1.00 loss per share (down from €1.16 profit in FY 2022). Revenue: €15.3b (down 17% from FY 2022). Net loss: €465.0m (down 186% from profit in FY 2022). Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 05International Chemical Investors S.E. agreed to acquire Superabsorbents business of Evonik.International Chemical Investors S.E. agreed to acquire Superabsorbents business of Evonik on March 4, 2024. The business to be sold generated sales of €892 million in 2023, with adjusted EBITDA in the mid double-digit million euro range. The final transfer of the business is planned for mid-2024 following approval by the relevant competition authorities.
お知らせ • Jan 16Lanxess Reportedly Seeks to Sell Polyurethane OpsLANXESS Aktiengesellschaft (XTRA:LXS) has initiated a process to sell its polyurethane business, which could be valued at between EUR 500 million (USD 547.2 million) and EUR 600 million, German paper Handelsblatt reported on January 15, 2024. The company has engaged Deutsche Bank to search for a buyer, Handelsblatt said, citing people familiar with the matter. Chemical companies such as Evonik Industries AG (XTRA:EVK), Stockmeier, or Plixxent, are considered possible interested parties. With the sale, Lanxess aims to completely exit the plastics market as the company has transformed into a producer of ingredients for food, cosmetics, and pharmaceuticals.
Reported Earnings • Nov 08Third quarter 2023 earnings released: €0.21 loss per share (vs €0.46 profit in 3Q 2022)Third quarter 2023 results: €0.21 loss per share (down from €0.46 profit in 3Q 2022). Revenue: €3.77b (down 23% from 3Q 2022). Net loss: €96.0m (down 145% from profit in 3Q 2022). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 11Second quarter 2023 earnings released: €0.58 loss per share (vs €0.64 profit in 2Q 2022)Second quarter 2023 results: €0.58 loss per share (down from €0.64 profit in 2Q 2022). Revenue: €3.89b (down 19% from 2Q 2022). Net loss: €270.0m (down 191% from profit in 2Q 2022). Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 10+ 3 more updatesEvonik Industries AG to Report Q1, 2024 Results on May 08, 2024Evonik Industries AG announced that they will report Q1, 2024 results on May 08, 2024
お知らせ • Jul 12Evonik Industries AG Revises Financial Guidance for the Full Year 2023Evonik Industries AG revised financial guidance for the full year 2023. The sales outlook is adjusted to a range between EUR 14 billion and EUR 16 billion (previously: EUR 17 billion to EUR 19 billion).
お知らせ • Jun 09RAG Stiftung Not in Hurry to Cut Evonik StakeRAG-Stiftung is not in a hurry to reduce its stake in chemicals firm Evonik Industries AG (XTRA:EVK) as the foundation is not under financial pressure, RAG chairman Bernd Toenjes said at a press conference as quotes by German paper Frankfurter Allgemeine Zeitung (FAZ). RAG Stiftung, which owns 54.9% in the chemicals company, plans to cut its stake to a blocking minority in the future. The shareholding may fall below the majority threshold soon. According to Toenjes, a convertible bond is due in 2024, providing an opportunity to reach 50% by the end of 2024. For the moment, Evonik remains one of the most important assets for RAG Stiftung.
Upcoming Dividend • May 25Upcoming dividend of €1.17 per share at 5.9% yieldEligible shareholders must have bought the stock before 01 June 2023. Payment date: 05 June 2023. The company is paying out more than 100% of its profits and is paying out 81% of its cash flow. Trailing yield: 5.9%. Within top quartile of Austrian dividend payers (5.4%). Higher than average of industry peers (4.0%).
Reported Earnings • May 10First quarter 2023 earnings released: EPS: €0.10 (vs €0.67 in 1Q 2022)First quarter 2023 results: EPS: €0.10 (down from €0.67 in 1Q 2022). Revenue: €4.01b (down 11% from 1Q 2022). Net income: €47.0m (down 85% from 1Q 2022). Profit margin: 1.2% (down from 7.0% in 1Q 2022). Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 03Full year 2022 earnings released: EPS: €1.16 (vs €1.61 in FY 2021)Full year 2022 results: EPS: €1.16 (down from €1.61 in FY 2021). Revenue: €18.5b (up 24% from FY 2021). Net income: €539.0m (down 28% from FY 2021). Profit margin: 2.9% (down from 5.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.6% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • Dec 30SABO S.p.A. acquired TAA derivatives business from Evonik Industries AG (XTRA:EVK).SABO S.p.A. agreed to acquire TAA derivatives business from Evonik Industries AG (XTRA:EVK) on October 21, 2022. On the sales price, no details are disclosed. The transaction is subject to approval by the competent Evonik committees. Around 250 employees to transfer to new owner. Around 250 people are working at the two production sites in Marl, Germany, and Liaoyang, China. The closing is expected to be in early 2023. SABO S.p.A. completed the acquisition of TAA derivatives business from Evonik Industries AG (XTRA:EVK) on December 29, 2022.
Reported Earnings • Nov 10Third quarter 2022 earnings released: EPS: €0.46 (vs €0.49 in 3Q 2021)Third quarter 2022 results: EPS: €0.46 (down from €0.49 in 3Q 2021). Revenue: €4.88b (up 26% from 3Q 2021). Net income: €214.0m (down 7.4% from 3Q 2021). Profit margin: 4.4% (down from 6.0% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • Nov 02Kensing, LLC completed the acquisition of Amphoteric Surfactants and Specialty Esters Manufacturing Operations in Hopewell, Virginia from Evonik Industries AG (XTRA:EVK).Kensing, LLC entered into an agreement to acquire Amphoteric Surfactants and Specialty Esters Manufacturing Operations in Hopewell, Virginia from Evonik Industries AG (XTRA:EVK) on July 28, 2022. The transaction is subject to regulatory approvals and customary closing conditions. The transaction is expected to close in the third quarter of 2022. Kensing, LLC completed the acquisition of Amphoteric Surfactants and Specialty Esters Manufacturing Operations in Hopewell, Virginia from Evonik Industries AG (XTRA:EVK) on November 1, 2022
お知らせ • Oct 12+ 2 more updatesEvonik Industries AG to Report Q2, 2023 Results on Aug 04, 2023Evonik Industries AG announced that they will report Q2, 2023 results on Aug 04, 2023
Reported Earnings • Aug 11Second quarter 2022 earnings released: EPS: €0.64 (vs €0.48 in 2Q 2021)Second quarter 2022 results: EPS: €0.64 (up from €0.48 in 2Q 2021). Revenue: €4.77b (up 31% from 2Q 2021). Net income: €297.0m (up 34% from 2Q 2021). Profit margin: 6.2% (up from 6.1% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is expected to shrink by 1.9% compared to a 14% growth forecast for the industry in Austria. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • Aug 03Kensing, LLC entered into an agreement to acquire Amphoteric Surfactants and Specialty Esters Manufacturing Operations in Hopewell, Virginia from Evonik Industries AG (XTRA:EVK)Kensing, LLC entered into an agreement to acquire Amphoteric Surfactants and Specialty Esters Manufacturing Operations in Hopewell, Virginia from Evonik Industries AG (XTRA:EVK) on July 28, 2022. The transaction is subject to regulatory approvals and customary closing conditions. The transaction is expected to close in the third quarter of 2022.
お知らせ • Jun 25Evonik Industries AG, Annual General Meeting, May 31, 2023Evonik Industries AG, Annual General Meeting, May 31, 2023. Agenda: Annual shareholders' meeting 2023.
Upcoming Dividend • May 19Upcoming dividend of €1.17 per shareEligible shareholders must have bought the stock before 26 May 2022. Payment date: 31 May 2022. Payout ratio is a comfortable 63% and this is well supported by cash flows. Trailing yield: 4.5%. Within top quartile of Austrian dividend payers (4.5%). Higher than average of industry peers (3.4%).
Reported Earnings • May 06First quarter 2022 earnings released: EPS: €0.67 (vs €0.41 in 1Q 2021)First quarter 2022 results: EPS: €0.67 (up from €0.41 in 1Q 2021). Revenue: €4.50b (up 34% from 1Q 2021). Net income: €314.0m (up 63% from 1Q 2021). Profit margin: 7.0% (up from 5.7% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 1.8%, compared to a 17% growth forecast for the industry in Austria. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Apr 22Evonik Industries AG Provides Earnings Guidance for the Full Year 2022Evonik Industries AG provided earnings guidance for the full year 2022. For the year, the company expects sales of between €15.5 billion and €16.5 billion.
Reported Earnings • Mar 05Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: €1.61 (up from €1.05 in FY 2020). Revenue: €15.0b (up 23% from FY 2020). Net income: €748.0m (up 53% from FY 2020). Profit margin: 5.0% (up from 4.0% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.1%. Over the next year, revenue is forecast to grow 2.9%, compared to a 12% growth forecast for the industry in Austria. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has remained flat.
お知らせ • Mar 04Evonik Industries AG to Report Q4, 2022 Results on Mar 02, 2023Evonik Industries AG announced that they will report Q4, 2022 results on Mar 02, 2023
Reported Earnings • Nov 06Third quarter 2021 earnings released: EPS €0.49 (vs €0.32 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €3.87b (up 33% from 3Q 2020). Net income: €231.0m (up 55% from 3Q 2020). Profit margin: 6.0% (up from 5.1% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 06Second quarter 2021 earnings released: EPS €0.48 (vs €0.26 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €3.64b (up 29% from 2Q 2020). Net income: €221.0m (up 77% from 2Q 2020). Profit margin: 6.1% (up from 4.4% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 04Evonik Industries AG (XTRA:EVK) acquired JeNaCell GmbH.Evonik Industries AG (XTRA:EVK) acquired JeNaCell GmbH on August 2, 2021. Upon completion the employees of JeNaCell will continue to work at the development and production site based in Jena, Germany and JeNaCell's portfolio will be integrated into Evonik's health care business. Evonik Industries AG (XTRA:EVK) completed the acquisition of JeNaCell GmbH on August 2, 2021.
お知らせ • Jun 23Orion Engineered Carbons S.A. Settles Dispute with Evonik Industries AGOrion Engineered Carbons S.A. announced its agreement with Evonik Industries AG to settle the arbitration proceedings which Orion (Germany) had commenced against an Evonik Industries AG affiliate in June 2019. The arbitration was launched by Orion to enforce - among others - indemnity claims covering capital expenditures and costs to remedy past violations of the U.S. Clean Air Act alleged by the U.S. Environmental Protection Agency (U.S. EPA). According to the settlement, Evonik agrees to make a one-time cash payment of €66.55 million (approximately $79.3 million) to Orion which resolves the claims and counterclaims the parties raised in the arbitration. The settled dispute between Orion and Evonik originates from the acquisition of the carbon black business by Rhône Capital and Triton after the business was spun-out of Evonik in 2011. The 2011 acquisition agreement provided for a partial indemnity from Evonik against various exposures, including capital investments, fines and costs arising in connection with U.S. Clean Air Act violations that allegedly occurred prior to the closing of the 2011 acquisition (i.e., under Evonik’s control). The respective claims raised by the U.S. EPA were ultimately resolved by a Consent Decree between Orion and the U.S. EPA in June 2018. Under the Consent Decree, Orion became obligated to install certain capital-intensive pollution control equipment at its U.S. carbon black plants. In June 2019, Orion initiated arbitration proceedings to enforce its environmental indemnity claims against Evonik, and Evonik in turn submitted certain counterclaims related to tax indemnities and cost reimbursements against Orion. The settlement now reached by Orion and Evonik terminates the arbitration and puts an end to a legal controversy that lasted for almost a decade.
Upcoming Dividend • May 27Upcoming dividend of €1.15 per shareEligible shareholders must have bought the stock before 03 June 2021. Payment date: 08 June 2021. Trailing yield: 4.0%. Within top quartile of Austrian dividend payers (3.2%). Higher than average of industry peers (2.3%).
Reported Earnings • May 07First quarter 2021 earnings released: EPS €0.41 (vs €0.29 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €3.36b (up 3.5% from 1Q 2020). Net income: €193.0m (up 42% from 1Q 2020). Profit margin: 5.7% (up from 4.2% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 10+ 1 more updateCassava Sciences Announces Pharmaceutical Supply Agreement for SimufilamCassava Sciences, Inc. announced it has entered into a drug supply agreement with Evonik Industries AG for simufilam. Under the agreement, Evonik will supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for the treatment of Alzheimer’s disease.
Reported Earnings • Mar 06Full year 2020 earnings releasedThe company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €12.2b (down 6.9% from FY 2019). Net income: €489.0m (down 35% from FY 2019). Profit margin: 4.0% (down from 5.7% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Mar 06Revenue beats expectationsRevenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 5.8%, compared to a 5.8% growth forecast for the Chemicals industry in Austria.
Is New 90 Day High Low • Feb 20New 90-day high: €28.03The company is up 18% from its price of €23.83 on 20 November 2020. The Austrian market is also up 18% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Chemicals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €53.22 per share.
お知らせ • Feb 13Evonik Industries AG to Report Q4, 2020 Results on Mar 04, 2021Evonik Industries AG announced that they will report Q4, 2020 results on Mar 04, 2021
Is New 90 Day High Low • Jan 29New 90-day high: €27.45The company is up 32% from its price of €20.82 on 30 October 2020. The Austrian market is up 39% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €52.93 per share.
Is New 90 Day High Low • Jan 06New 90-day high: €27.33The company is up 16% from its price of €23.50 on 08 October 2020. The Austrian market is up 27% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €53.41 per share.
お知らせ • Jan 06Evonik Industries AG (XTRA:EVK) completed the acquisition of LACTEL Absorbable Polymer Product Line of DURECT Corporation (NasdaqCM:DRRX) for $15 million.Evonik Industries AG (XTRA:EVK) signed an agreement to acquire LACTEL Absorbable Polymer Product Line of DURECT Corporation (NasdaqCM:DRRX) for $15 million on December 4, 2020. Under the terms of the agreement, Evonik agreed to pay DURECT the sum of $15 million in exchange for certain assets and liabilities associated with LACTEL product line based in Birmingham, Alabama, plus an additional potential payment based on full year EBITDAS results. The consideration is subject to adjustments based on the year-end net working capital. An offer will be extended to each of the 15 employees of DURECT located in Birmingham, Alabama, which are associated with the LACTEL® business to transition to Evonik. The transaction is subject to certain customary closing conditions and is expected to occur by the first quarter of 2021. Evonik Industries AG (XTRA:EVK) completed the acquisition of LACTEL Absorbable Polymer Product Line of DURECT Corporation (NasdaqCM:DRRX) on January 4, 2021.
Is New 90 Day High Low • Dec 16New 90-day high: €26.75The company is up 15% from its price of €23.28 on 17 September 2020. The Austrian market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €44.44 per share.
お知らせ • Dec 12Evonik Industries AG to Report Q2, 2021 Results on Aug 05, 2021Evonik Industries AG announced that they will report Q2, 2021 results on Aug 05, 2021
Is New 90 Day High Low • Nov 24New 90-day high: €25.11The company is up 2.0% from its price of €24.67 on 26 August 2020. The Austrian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €39.61 per share.
お知らせ • Nov 20+ 1 more updateEvonik Industries AG to Report Q3, 2021 Results on Nov 04, 2021Evonik Industries AG announced that they will report Q3, 2021 results on Nov 04, 2021
Reported Earnings • Nov 05Third quarter 2020 earnings released: EPS €0.32The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2020 results: Revenue: €2.92b (down 9.7% from 3Q 2019). Net income: €149.0m (down 2.6% from 3Q 2019). Profit margin: 5.1% (up from 4.7% in 3Q 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.
Analyst Estimate Surprise Post Earnings • Nov 05Revenue beats expectationsRevenue exceeded analyst estimates by 0.1%. Over the next year, revenue is forecast to grow 3.9% while the growth in Chemicals industry in Austria is expected to stay flat.
Is New 90 Day High Low • Oct 21New 90-day low: €21.93The company is down 12% from its price of €24.87 on 23 July 2020. The Austrian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €36.16 per share.
Is New 90 Day High Low • Sep 26New 90-day low: €21.99The company is down 4.0% from its price of €22.84 on 26 June 2020. The Austrian market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €40.52 per share.
お知らせ • Aug 27Evonik Industries AG (XTRA:EVK) entered into a definitive agreement to acquire Porocel Corporation for $210 million.Evonik Industries AG (XTRA:EVK) entered into a definitive agreement to acquire Porocel Corporation for $210 million on August 26, 2020. The purchase price (enterprise value) is 9.1x times adjusted earnings before interest, tax, depreciation and amortization (EBITDA) in 2019. The transaction will be financed out of Evonik's strong cash position. Porocel generated sales of approximately $100 million and EBITDA of about $23 million in 2019. The transaction is expected to close by the end of 2020 and is subject to approval by the relevant authorities. Evonik expects to increase sales of the combined catalyst business to significantly more than $591 million (€500 million) by the end of 2025 without the need for investment in new capacities. RBC Capital Markets acted as financial advisor and Thompson Hine LLP acted as legal advisor to Porocel. Dieter Schmitz (US), Matthew Grant (Canada), Tracy Wut (China), Jean-Francois Findling (Luxembourg), Andrew Martin (Singapore), John Murphy, Garry Jaunal, Kai Kramer, Doug Sanders, Jessica Wicha, Brian Zurawski and Richard Wells of Baker McKenzie acted as legal advisor to Evonik Industries.
お知らせ • Jul 31Evonik Industries AG (XTRA:EVK) completed the acquisition of Innovativehealth Group,s.lEvonik Industries AG (XTRA:EVK) entered into an agreement to acquire to acquire Innovativehealth Group,s.l on March 19, 2020. Innovativehealth will be part of Evonik's Care Solutions Business Line. The transaction is expected to close before the end of March 2020. Evonik Industries AG (XTRA:EVK) completed the acquisition of Innovativehealth Group,s.l on April 1, 2020. Innovativehealth GROUP,S.L. will be part of Evonik's Care Solutions Business Line.
お知らせ • Jul 30United Initiators GmbH completed the acquisition of Hydrogen Peroxide (H2O2) plant of Evonik Industries AG (XTRA:EVK).United Initiators GmbH agreed to acquire Hydrogen Peroxide (H2O2) plant of Evonik Industries AG (XTRA:EVK) on January 28, 2020. The sale has been initiated to address the Competition Bureau about its proposed transaction for the takeover of PeroxyChem Holding Company LLC. The deal has been approved by the Competition Bureau. United Initiators GmbH completed the acquisition of Hydrogen Peroxide (H2O2) plant of Evonik Industries AG (XTRA:EVK) on January 28, 2020.